DreaMed
AI solutions and personalized support for optimized insulin therapy, turning real-time patient data into actionable treatment. #t1d #t2d #diabetes.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $3.0m | Early VC | |
| Total Funding | 000k | ||
Related Content
DreaMed is an Israeli company founded in 2014 that operates in the digital health sector, specializing in diabetes management. The company has developed endo.digital, a cloud-based Software as a Service (SaaS) platform that functions as an AI-driven clinical decision support system for healthcare providers.
The platform gathers data from various diabetes management devices, such as glucose monitors and insulin pumps. It then analyzes this information to provide personalized treatment recommendations for patients with diabetes. This system is designed to assist endocrinologists and other healthcare professionals in optimizing patient care and making data-informed treatment adjustments. The business model is based on subscriptions to the endo.digital platform by healthcare organizations.
The company has a history of collaboration, including a partnership with Medtronic to develop an artificial pancreas system. DreaMed has also secured multiple FDA clearances for its technology, underscoring its clinical validation.
Keywords: diabetes management, clinical decision support, SaaS, digital health, personalized medicine, patient data analytics, endocrinology, medical AI, FDA cleared, treatment optimization